{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:22Z","timestamp":1791976522742,"version":"4.4.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Growth hormone deficiency (GHD) in children is currently treated with daily injections of GH, which can be burdensome for patients and their parents\/guardians. Somapacitan is a GH derivative in development for once-weekly treatment of GHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This work aimed to assess the efficacy and safety of somapacitan, and associated disease\/treatment burden, after 4 years of treatment and 1 year after switching to somapacitan from daily GH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This long-term safety extension of a multicenter, controlled phase 2 trial (NCT02616562) took place at 29 sites in 11 countries. Patients were prepubertal, GH-naive children with GHD. Fifty patients completed 4 years of treatment. Patients in the pooled group received somapacitan (0.04, 0.08, 0.16 mg\/kg\/week) for 1 year, followed by the highest dose (0.16 mg\/kg\/week) for 3 years. Patients in the switched group received daily GH 0.034 mg\/kg\/day for 3 years, then somapacitan 0.16 mg\/kg\/week for 1 year. Main outcome measures were height velocity (HV), change from baseline in HV SD score (SDS), change from baseline in height SDS, disease burden, and treatment burden for patients and parents\/guardians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Changes from baseline in HV and HV SDS were similar and as expected in both groups. Observer-reported outcomes showed that patients and parents\/guardians seem to have experienced a reduced treatment burden when switching from daily GH to somapacitan. Most parents\/guardians (81.8%) strongly\/very strongly preferred somapacitan over daily GH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Somapacitan showed similar efficacy and safety in patients who continued somapacitan treatment and those who switched from daily GH to somapacitan. Once-weekly injections may lead to a reduced treatment burden relative to once-daily injections. A plain-language summary of this work is available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad183","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T20:30:21Z","timestamp":1680208221000},"page":"2569-2578","source":"Crossref","is-referenced-by-count":39,"title":["Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment\/Disease Burden Results From REAL 3"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-4976","authenticated-orcid":false,"given":"Lars","family":"S\u00e4vendahl","sequence":"first","affiliation":[{"name":"Department of Women's and Children's Health, Karolinska Institutet and Pediatric Endocrinology Unit, Karolinska University Hospital , 171 64 Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-4732","authenticated-orcid":false,"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, and University Medical Center Ljubljana , Ljubljana 1000 , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"H\u00f8jby Rasmussen","sequence":"additional","affiliation":[{"name":"Clinical Drug Development, Novo Nordisk A\/S , S\u00f8borg 2860 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl","family":"Brod","sequence":"additional","affiliation":[{"name":"The Brod Group , Mill Valley, CA 94941 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"R\u00f6hrich","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Rare Endocrine Disorders, Novo Nordisk Health Care AG , 8050 Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Saenger","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, NYU Langone Health , Mineola, NY 11501 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3429-3246","authenticated-orcid":false,"given":"Reiko","family":"Horikawa","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Division, National Center for Child Health and Development , Tokyo 157-8535 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"issue":"6","key":"2023091800461806900_dgad183-B1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000452150","article-title":"Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"2023091800461806900_dgad183-B2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41574-021-00539-5","article-title":"Advances in differential diagnosis and management of growth hormone deficiency in children","volume":"17","author":"Hage","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"2023091800461806900_dgad183-B3","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s11136-017-1529-1","article-title":"Understanding burden of illness for child growth hormone deficiency","volume":"26","author":"Brod","year":"2017","journal-title":"Qual Life Res"},{"issue":"6","key":"2023091800461806900_dgad183-B4","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations\u2014current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J Clin Endocrinol Metabol"},{"issue":"5","key":"2023091800461806900_dgad183-B5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40271-017-0237-9","article-title":"Understanding treatment burden for children treated for growth hormone deficiency","volume":"10","author":"Brod","year":"2017","journal-title":"Patient"},{"issue":"1","key":"2023091800461806900_dgad183-B6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pedn.2011.12.006","article-title":"Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers","volume":"28","author":"Kremidas","year":"2013","journal-title":"J Pediatr Nurs"},{"key":"2023091800461806900_dgad183-B7","author":"Food and Drug Administration","year":"2009"},{"issue":"3","key":"2023091800461806900_dgad183-B8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s41669-020-00252-5","article-title":"Psychometric validation of the Growth Hormone Deficiency\u2013Child Impact Measure (GHD-CIM)","volume":"5","author":"Brod","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"2023091800461806900_dgad183-B9","author":"Brod"},{"key":"2023091800461806900_dgad183-B10","author":"Novo Nordisk A\/S","year":"2021"},{"key":"2023091800461806900_dgad183-B11","author":"Novo Nordisk Inc","year":"2020"},{"key":"2023091800461806900_dgad183-B12","author":"Novo Nordisk","year":"2022"},{"issue":"1","key":"2023091800461806900_dgad183-B13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11102-022-01283-3","article-title":"Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency","volume":"26","author":"Takahashi","year":"2022","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"2023091800461806900_dgad183-B14","first-page":"A1164","article-title":"Once-weekly somapacitan vs daily growth hormone in growth hormone deficiency: 2-year safety results from REAL 3, a randomized phase 2 trial","volume":"4","author":"S\u00e4vendahl","year":"2020","journal-title":"J Endocr Soc"},{"issue":"5","key":"2023091800461806900_dgad183-B15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/clinem\/dgab928","article-title":"Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3","volume":"107","author":"S\u00e4vendahl","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"key":"2023091800461806900_dgad183-B16","author":"S\u00e4vendahl","year":"2023"},{"issue":"3","key":"2023091800461806900_dgad183-B17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/adc.51.3.170","article-title":"Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty","volume":"51","author":"Tanner","year":"1976","journal-title":"Arch Dis Child"},{"key":"2023091800461806900_dgad183-B18","author":"EMEA Committee for Medicinal products for Human Use","year":"2006"},{"issue":"1","key":"2023091800461806900_dgad183-B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s41669-018-0082-3","article-title":"Assessing the impact of growth hormone deficiency (GHD) in adults: interpreting change of the Treatment-Related Impact Measure\u2013Adult Growth Hormone Deficiency (TRIM-AGHD)","volume":"3","author":"Brod","year":"2019","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"2023091800461806900_dgad183-B20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s41669-022-00373-z","article-title":"Psychometric validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB)","volume":"7","author":"Brod","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"2023091800461806900_dgad183-B21","author":"S\u00e4vendahl","year":"2023"},{"issue":"6","key":"2023091800461806900_dgad183-B22","doi-asserted-by":"crossref","first-page":"R212","DOI":"10.1530\/EC-18-0099","article-title":"The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders","volume":"7","author":"Blum","year":"2018","journal-title":"Endocr Connect"},{"issue":"12","key":"2023091800461806900_dgad183-B23","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1210\/clinem\/dgac513","article-title":"Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial","volume":"107","author":"Miller","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023091800461806900_dgad183-B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/EJE-21-1167","article-title":"Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency","volume":"187","author":"Kildemoes","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023091800461806900_dgad183-B25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1210\/clinem\/dgaa775","article-title":"Optimal monitoring of weekly IGF-I levels during growth hormone therapy with once-weekly somapacitan","volume":"106","author":"Kildemoes","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2023091800461806900_dgad183-B26","doi-asserted-by":"crossref","first-page":"637209","DOI":"10.3389\/fendo.2021.637209","article-title":"Usefulness and potential pitfalls of long-acting growth hormone analogs","volume":"12","author":"Yuen","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023091800461806900_dgad183-B27","doi-asserted-by":"publisher","DOI":"10.1159\/000523791","article-title":"Long-acting growth hormone preparations and their use in children with growth hormone deficiency","author":"Pampanini","year":"2022","journal-title":"Horm Res Paediatr"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad183\/50276943\/dgad183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/10\/2569\/51533409\/dgad183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/10\/2569\/51533409\/dgad183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T20:47:14Z","timestamp":1694983634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/10\/2569\/7095611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,3,30]]},"published-print":{"date-parts":[[2023,9,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad183","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,3,30]]}}}